ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A MULTICENTRIC RANDOMIZED TRIAL TESTING BONE-MARROW TRANSPLANTATION AS POSTREMISSION THERAPY

Purpose: In a prospective multicenter study, we analyzed the benefits of allogeneic bone marrow transplantation (BMT) in a nonselected group of adult patients with acute lymphoblastic leukemia (ALL) and, by a randomized trial, evaluated the effectiveness of autologous BMT over chemotherapy as postremission therapy in patients younger than 50 years who were not candidates for allogeneic BMT. Patients and Methods: After induction therapy that randomized patients to receive one of two anthracycline-containing regimens, either daunorubicin (DNR) or zorubicin (ZRB), patients were assigned to postremission treatment according to age and results of HLA typing. Patients younger than 40 years with an HLA-identical sibling (group 1) were scheduled to receive cyclophosphamide 60 mg/kg on days 1 and 2, total-body irradiation (TBI), and allogeneic BMT. Patients older than 50 years (group 2) received the chemotherapy arm composed of three monthly consolidation courses (DNR or ZRB, cytarabine, and asparaginase) followed by maintenance chemotherapy (modified L10 regimen). The remaining population (group 3) was randomly assigned to receive, after the three 1-month consolidation courses, either the chemotherapy arm or autologous BMT following a conditioning regimen similar to that of group 1. Results: Of the 572 assessable patients, 436 achieved complete remission (78% ± 2% for DNR v 74% ± 3% for ZRB;P = .3). The estimated 3-year disease-free survival (DFS) rate for the 116 patients included in group 1 was 43% ± 5%. Both autologous BMT (95 patients) and chemotherapy (96 patients) produced comparable 3-year DFS rates (39% ± 5% v 32% ± 5%) and survival durations (49% ± 5% v 42% ± 5%). However, late relapses after 36 months were mainly observed in the chemotherapy arm. Conclusion: This first interim analysis did not demonstrate a benefit of this autologous BMT procedure over classical maintenance chemotherapy in patients with ALL who received consolidation chemotherapy.